631 related articles for article (PubMed ID: 20941354)
21. The synergy of honokiol and fluconazole against clinical isolates of azole-resistant Candida albicans.
Jin J; Guo N; Zhang J; Ding Y; Tang X; Liang J; Li L; Deng X; Yu L
Lett Appl Microbiol; 2010 Sep; 51(3):351-7. PubMed ID: 20681969
[TBL] [Abstract][Full Text] [Related]
22. Loss of C-5 Sterol Desaturase Activity in
Luna-Tapia A; Butts A; Palmer GE
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30323044
[TBL] [Abstract][Full Text] [Related]
23. Impact of Farnesol as a Modulator of Efflux Pumps in a Fluconazole-Resistant Strain of
Černáková L; Dižová S; Gášková D; Jančíková I; Bujdáková H
Microb Drug Resist; 2019; 25(6):805-812. PubMed ID: 30785845
[No Abstract] [Full Text] [Related]
24. Vacuolar Sequestration of Azoles, a Novel Strategy of Azole Antifungal Resistance Conserved across Pathogenic and Nonpathogenic Yeast.
Khandelwal NK; Wasi M; Nair R; Gupta M; Kumar M; Mondal AK; Gaur NA; Prasad R
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30642932
[TBL] [Abstract][Full Text] [Related]
25. Antifungal activity of ribavirin used alone or in combination with fluconazole against Candida albicans is mediated by reduced virulence.
Zhang M; Yan H; Lu M; Wang D; Sun S
Int J Antimicrob Agents; 2020 Jan; 55(1):105804. PubMed ID: 31605727
[TBL] [Abstract][Full Text] [Related]
26. The Celecoxib Derivative AR-12 Has Broad-Spectrum Antifungal Activity In Vitro and Improves the Activity of Fluconazole in a Murine Model of Cryptococcosis.
Koselny K; Green J; DiDone L; Halterman JP; Fothergill AW; Wiederhold NP; Patterson TF; Cushion MT; Rappelye C; Wellington M; Krysan DJ
Antimicrob Agents Chemother; 2016 Dec; 60(12):7115-7127. PubMed ID: 27645246
[TBL] [Abstract][Full Text] [Related]
27. Resistance in human pathogenic yeasts and filamentous fungi: prevalence, underlying molecular mechanisms and link to the use of antifungals in humans and the environment.
Jensen RH
Dan Med J; 2016 Oct; 63(10):. PubMed ID: 27697142
[TBL] [Abstract][Full Text] [Related]
28. Berberine Antifungal Activity in Fluconazole-Resistant Pathogenic Yeasts: Action Mechanism Evaluated by Flow Cytometry and Biofilm Growth Inhibition in Candida spp.
da Silva AR; de Andrade Neto JB; da Silva CR; Campos Rde S; Costa Silva RA; Freitas DD; do Nascimento FB; de Andrade LN; Sampaio LS; Grangeiro TB; Magalhães HI; Cavalcanti BC; de Moraes MO; Nobre Júnior HV
Antimicrob Agents Chemother; 2016 Jun; 60(6):3551-7. PubMed ID: 27021328
[TBL] [Abstract][Full Text] [Related]
29. Combination of fluconazole with non-antifungal agents: a promising approach to cope with resistant Candida albicans infections and insight into new antifungal agent discovery.
Liu S; Hou Y; Chen X; Gao Y; Li H; Sun S
Int J Antimicrob Agents; 2014 May; 43(5):395-402. PubMed ID: 24503221
[TBL] [Abstract][Full Text] [Related]
30. Fcr1p inhibits development of fluconazole resistance in Candida albicans by abolishing CDR1 induction.
Shen H; An MM; Wang de J; Xu Z; Zhang JD; Gao PH; Cao YY; Cao YB; Jiang YY
Biol Pharm Bull; 2007 Jan; 30(1):68-73. PubMed ID: 17202662
[TBL] [Abstract][Full Text] [Related]
31. Tetrandrine enhances the antifungal activity of fluconazole in a murine model of disseminated candidiasis.
Shi J; Li S; Gao A; Zhu K; Zhang H
Phytomedicine; 2018 Jul; 46():21-31. PubMed ID: 30097119
[TBL] [Abstract][Full Text] [Related]
32. Plagiochin E, a botanic-derived phenolic compound, reverses fungal resistance to fluconazole relating to the efflux pump.
Guo XL; Leng P; Yang Y; Yu LG; Lou HX
J Appl Microbiol; 2008 Mar; 104(3):831-8. PubMed ID: 18194250
[TBL] [Abstract][Full Text] [Related]
33. In vitro synergy of pseudolaric acid B and fluconazole against clinical isolates of Candida albicans.
Guo N; Ling G; Liang X; Jin J; Fan J; Qiu J; Song Y; Huang N; Wu X; Wang X; Deng X; Deng X; Yu L
Mycoses; 2011 Sep; 54(5):e400-6. PubMed ID: 21910756
[TBL] [Abstract][Full Text] [Related]
34.
Nishimoto AT; Wiederhold NP; Flowers SA; Zhang Q; Kelly SL; Morschhäuser J; Yates CM; Hoekstra WJ; Schotzinger RJ; Garvey EP; Rogers PD
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30910896
[TBL] [Abstract][Full Text] [Related]
35. Potent in vitro synergism of fluconazole and berberine chloride against clinical isolates of Candida albicans resistant to fluconazole.
Quan H; Cao YY; Xu Z; Zhao JX; Gao PH; Qin XF; Jiang YY
Antimicrob Agents Chemother; 2006 Mar; 50(3):1096-9. PubMed ID: 16495278
[TBL] [Abstract][Full Text] [Related]
36. Contribution of clinically derived mutations in ERG11 to azole resistance in Candida albicans.
Flowers SA; Colón B; Whaley SG; Schuler MA; Rogers PD
Antimicrob Agents Chemother; 2015 Jan; 59(1):450-60. PubMed ID: 25385095
[TBL] [Abstract][Full Text] [Related]
37. Divergent functions of three Candida albicans zinc-cluster transcription factors (CTA4, ASG1 and CTF1) complementing pleiotropic drug resistance in Saccharomyces cerevisiae.
Coste AT; Ramsdale M; Ischer F; Sanglard D
Microbiology (Reading); 2008 May; 154(Pt 5):1491-1501. PubMed ID: 18451058
[TBL] [Abstract][Full Text] [Related]
38. Colony and Single Cell Level Analysis of the Heterogeneous Response of
Altamirano S; Simmons C; Kozubowski L
Front Cell Infect Microbiol; 2018; 8():203. PubMed ID: 29971221
[No Abstract] [Full Text] [Related]
39. Cryptococcus neoformans Yap1 is required for normal fluconazole and oxidative stress resistance.
Paul S; Doering TL; Moye-Rowley WS
Fungal Genet Biol; 2015 Jan; 74():1-9. PubMed ID: 25445311
[TBL] [Abstract][Full Text] [Related]
40. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003.
Hsueh PR; Lau YJ; Chuang YC; Wan JH; Huang WK; Shyr JM; Yan JJ; Yu KW; Wu JJ; Ko WC; Yang YC; Liu YC; Teng LJ; Liu CY; Luh KT
Antimicrob Agents Chemother; 2005 Feb; 49(2):512-7. PubMed ID: 15673726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
